Enveric Biosciences (ENVB) EBITDA (2010 - 2026)
Enveric Biosciences (ENVB) posted EBITDA of -$1.6 million for Q1 2026, up 25.56% sequentially from -$2.2 million in Q4 2025, and up 25.34% YoY from -$1.3 million in Q1 2025.
Enveric Biosciences (ENVB) EBITDA (2010 - 2026) Analysis & Trends
Enveric Biosciences has reported EBITDA for 17 years, with the latest figure at -$1.6 million in Q1 2026.
- Quarterly EBITDA rose 25.34% year-over-year to -$1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.2 million (up 12.01% YoY) and the FY2025 annual result came in at -$8.8 million, up 8.91% from the prior year.
- EBITDA grew to -$1.6 million in Q1 2026 per ENVB's latest filing, from -$2.2 million in the prior quarter.
- Over five years, EBITDA peaked at -$1.6 million in Q1 2026 and troughed at -$12.3 million in Q4 2022.
- A 5-year average of -$3.8 million and a median of -$2.5 million in 2025 frame the typical range for EBITDA.
- The sharpest annual moves came in 2022 and 2023: EBITDA plunged 60.85% in 2022, then jumped 80.54% in 2023.
- Over 5 years, EBITDA stood at -$12.3 million in 2022, then surged by 80.54% to -$2.4 million in 2023, then plunged by 33.11% to -$3.2 million in 2024, then surged by 30.87% to -$2.2 million in 2025, then advanced by 25.56% to -$1.6 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$1.6 million, -$2.2 million, and -$1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Enveric Biosciences | 5.42 Mn | -2.87 Mn | - | -3.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.63 Mn |
| Dec 31, 2025 | -2.19 Mn |
| Sep 30, 2025 | -1.87 Mn |
| Jun 30, 2025 | -2.52 Mn |
| Mar 31, 2025 | -2.19 Mn |
| Dec 31, 2024 | -3.17 Mn |
| Sep 30, 2024 | -2.08 Mn |
| Jun 30, 2024 | -1.90 Mn |
| Mar 31, 2024 | -2.48 Mn |
| Dec 31, 2023 | -2.38 Mn |
| Sep 30, 2023 | -3.45 Mn |
| Jun 30, 2023 | -5.76 Mn |
| Mar 31, 2023 | -4.86 Mn |
| Dec 31, 2022 | -12.26 Mn |
| Sep 30, 2022 | -5.66 Mn |
| Jun 30, 2022 | -4.71 Mn |
| Mar 31, 2022 | -4.80 Mn |
| Dec 31, 2021 | -50.98 Mn |
| Sep 30, 2021 | -3.52 Mn |
| Jun 30, 2021 | -3.36 Mn |